Transfer of Sanofi rhinitis allergy drug to OTC, or impact on conbine
-
Last Update: 2013-08-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: great wisdom aastocks news agency 2013-8-2, the US Food and drug administration ruled on Wednesday that Sanofi's anti allergy drug Triamcinolone Acetonide Nasal Spray (Nasacort AQ) can be identified as an over-the-counter drug The news may have a negative impact on related domestic sectors Triamcinolone Acetonide Nasal Spray will become the first over-the-counter nasal steroid drug in the United States, according to Reuters reported on Wednesday So far, the spray has been sold as an over-the-counter drug in over 10 countries worldwide Sanofi said that over-the-counter drugs and consumer goods will be expected to make up for the loss of the company's new drug protection period It is understood that before Triamcinolone Acetonide Nasal Spray lost its protection period, it contributed $375 million a year to the company, compared with less than $100 million last year Triamcinolone acetonide is a powerful glucocorticoid It has obvious antiallergic effect and can obviously alleviate the nasal symptoms of allergic rhinitis A listed company in the domestic production of Triamcinolone Acetonide Nasal Spray is Kang Bei.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
